For research use only
| Cat No. | ABC-TC0657 |
| Product Type | Human Breast Cancer Cell Lines |
| Cell Type | Epithelial |
| Species | Human |
| Growth Conditions | 37 ℃ |
| Source Organ | Breast |
| Product Code | MDA-MB 468; MDA-MB468; MDAMB468; MDA-468; MDA468; MB468; MD Anderson-Metastatic Breast-468 |
MDA-MB-468 Breast Cancer Cells are used for modeling triple-negative breast cancer behavior, EGFR signaling, and cytotoxic compound response.
MDA-MB-468 is a human breast cancer cell line derived from the pleural effusion of a 51-year-old woman with metastatic adenocarcinoma. These cells exhibit epithelial morphology and are classified as triple-negative breast cancer (TNBC) cells, lacking expression of estrogen receptor (ER), progesterone receptor (PR), and HER2/neu. MDA-MB-468 cells are characterized by an abnormal near-triploid karyotype and harbor a homozygous deletion of PTEN, resulting in constitutive activation of the PI3K/AKT pathway. They also overexpress EGFR, making them a widely used model for EGFR-targeted therapy research. These cells display tumorigenic and metastatic properties in xenograft models and are extensively employed in cancer signaling, drug resistance, and apoptosis studies.
| Product Code | MDA-MB 468; MDA-MB468; MDAMB468; MDA-468; MDA468; MB468; MD Anderson-Metastatic Breast-468 |
| Species | Human |
| Cat.No | ABC-TC0657 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Epithelial |
| Growth Mode | Adherent |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃ |
| Source Organ | Breast |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Breast Cancer Cell Lines |
MDA-MB-468 is a key model for investigating the gene expression of basal-like TNBC and identifying the signal activators and transducers in signaling pathways that regulate or suppress cell growth and survival. Unlike ER-positive and HER2-amplified cancers, TNBC exhibits stronger resistance to hormone and HER2-targeted therapies, primarily due to the absence of frequent oncogenic driver mutations. Therefore, MDA-MB-468 is crucial in breast cancer research. For instance, the application of MDA-MB-468 in TNBC xenograft models has confirmed the inhibitory effect of IMMU-132, an antibody-drug conjugate targeting Trop-2, on tumor growth.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
